Bioprinting of kidney in vitro models: cells, biomaterials, and manufacturing techniques

  title={Bioprinting of kidney in vitro models: cells, biomaterials, and manufacturing techniques},
  author={Maaike F J Fransen and G. Addario and C. Bouten and F. Halary and L. Moroni and C. Mota},
  journal={Essays in Biochemistry},
  pages={587 - 602}
Abstract The number of patients with end-stage renal disease is continuously increasing worldwide. The only therapies for these patients are dialysis and organ transplantation, but the latter is limited due to the insufficient number of donor kidneys available. Research in kidney disease and alternative therapies are therefore of outmost importance. In vitro models that mimic human kidney functions are essential to provide better insights in disease and ultimately novel therapies. Bioprinting… Expand

Figures and Tables from this paper


Microfluidic bioprinting towards a renal in vitro model
Microfluidic bioprinting strategy could be used to build a novel 3D kidney in vitro model to investigate underlying pathomechanism of kidney diseases. Expand
Autologous Cells for Kidney Bioengineering
Recent breakthroughs in pluripotent stem cell biology that have led to the development of autologous renal progenitor cells capable of differentiating to all renal cell types are highlighted and how these cells could be combined with appropriate scaffolds to develop a bioengineered kidney. Expand
Stem cell-derived kidney cells and organoids: Recent breakthroughs and emerging applications.
This review will give a comprehensive overview over current PSC-based protocols for the generation of renal-like cells, precursors and organoids, and their current and potential applications in regenerative medicine, compound screening, disease modelling and bioartificial organs. Expand
Bioengineering strategies for nephrologists: kidney was not built in a day
This review will go through the different approaches that have been developed over the years to build kidneys, and examines how organoids and microfluidic devices could answer important pathophysiological questions and model the path toward creating in vitro functional organs, for example through 3D biop printing. Expand
Bioprinting: From Tissue and Organ Development to in Vitro Models
The continuous convergence of the experts in the fields of material sciences, cell biology, engineering, and many other disciplines will gradually allow us to overcome the barriers identified on the demanding path toward manufacturing and adoption of tissue and organ replacements. Expand
Prospect for kidney bioengineering: shortcomings of the status quo
Progress in stem cells-based therapies, decellularization techniques and the more recent scientific know-how for the use of the 3D printer and kidney-on-chip could lead to a perfect cellular-based therapy, the futuristic creation of a bioengineered kidney in the lab or to a valid bioartificial alternative. Expand
In Vitro Human Tissues via Multi-material 3-D Bioprinting
The Lewis Bioprinting team created a thick, stem cell-laden vascularised tissue that was controllably differentiated toward an osteogenic lineage in situ, and a 3D kidney tissue that recapitulated the proximal tubule, a sub-unit of the nephron responsible for solute reabsorption. Expand
Three-dimensional cell-printing of advanced renal tubular tissue analogue.
The renal subcapsular transplantation of the hollow tubes showed a long-term graft survival with the therapeutic capability of the tubular constructs in in vivo model of renal disease, which serves their applicability in regenerative medicine. Expand
Mimicking the Kidney: A Key Role in Organ-on-Chip Development
An extensive review of the studies focused on the development of a nephron-on-chip device is provided, highlighting the need for better models that mimic the functional unit of the kidney. Expand
Organotypic and microphysiological models of liver, gut and kidney for studies of drug metabolism, pharmacokinetics and toxicity.
Recent advances in organotypic and microphysiological culture models of human tissues can improve drug development and contribute to an amelioration of clinical attrition rates, but further validation, benchmarking and consolidation efforts are needed to achieve more widespread dissemination and eventually regulatory acceptance of these novel tools. Expand